Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases

Fineline Cube Jul 6, 2026
Company Deals

iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations

Fineline Cube Jul 6, 2026
Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Deals

Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development

Fineline Cube Jul 23, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary...

Company Deals

Shanghai Medicilon and Jiangsu Hengrui Join Forces to Advance Pre-Clinical Drug Evaluation

Fineline Cube Jul 23, 2024

Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...

Company Drug

AccurEdit Therapeutics Receives CDE Approval for Gene Editing Drug ART001 Targeting Amyloidosis

Fineline Cube Jul 23, 2024

AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading specialist in gene editing therapies based in China,...

Company Deals

Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D

Fineline Cube Jul 23, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...

Company Drug

ICER Analysis Flags Pfizer’s ATTR-CM Therapy Vyndamax/Vyndaqel as Costly, Suggests Price Cut

Fineline Cube Jul 22, 2024

The Institute for Clinical and Economic Review (ICER), a US-based non-profit organization specializing in drug...

R&D

Beijing Launches Bio-Park: A New Hub for International Pharmaceutical Innovation

Fineline Cube Jul 22, 2024

Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park...

Company Deals Medical Device

MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China

Fineline Cube Jul 22, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...

Policy / Regulatory

China’s NMPA and NHC Implement New Rules for Temporary Import of Urgent Medical Devices

Fineline Cube Jul 22, 2024

The National Medical Products Administration (NMPA) and the National Health Commission have issued the Management...

Company Deals Drug

Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion

Fineline Cube Jul 22, 2024

Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered...

Company Drug

Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial

Fineline Cube Jul 22, 2024

Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...

Policy / Regulatory

China Unveils Ambitious Healthcare Reforms at 20th Central Committee Plenary Session

Fineline Cube Jul 22, 2024

The third plenary session of the 20th Central Committee of the Communist Party of China...

Company Drug

Jiangsu Hengrui Receives NMPA Approval to Study CDK 4/6 Inhibitor Dalpiciclib in Combination with HRS-1358 for Breast Cancer

Fineline Cube Jul 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has received...

Company Drug

Hansoh Pharmaceutical’s EGFR Inhibitor Ameile Files for Adjuvant Therapy Approval with NMPA

Fineline Cube Jul 22, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading biopharmaceutical company based in China, has...

Company Drug

NMPA Approves Chengdu Chipscreen’s Bilessglu for Type 2 Diabetes in Combination with Metformin

Fineline Cube Jul 22, 2024

The National Medical Products Administration (NMPA) has granted approval for Shenzhen Chipscreen Biosciences Co., Ltd...

Company Deals

Eisai Forges Partnerships with Chinese Firms to Strengthen Alzheimer’s Disease Market Presence

Fineline Cube Jul 22, 2024

Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with...

Company Deals

MedSci Healthcare’s Bioon.com Partners with Wego Group to Boost Local Innovation and Product Promotion

Fineline Cube Jul 22, 2024

MedSci Healthcare Co., Ltd (HKG: 2415), a Chinese healthcare company, has announced that its subsidiary,...

Company Deals

Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies

Fineline Cube Jul 22, 2024

Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a...

Company Deals

Huadong Medicine to Expand TCM Footprint with Acquisition of Hengba Pharmaceutical

Fineline Cube Jul 22, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced its intention to...

Company Deals

Beijing X-Magtech Secures Over RMB 100 Million in Series A+ Funding for Magnetic Field Measurement Tech

Fineline Cube Jul 22, 2024

Beijing X-Magtech Technologies, a specialist in ultra-weak magnetic field measurement technology, has reportedly secured over...

Company Deals

BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia

Fineline Cube Jul 22, 2024

Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE:...

Posts pagination

1 … 351 352 353 … 690

Recent updates

  • Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology
  • Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases
  • iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations
  • Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
  • Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology

Company Deals

Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases

Company Deals

iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.